Article Information
History
- November 7, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Maria Lozano-Rabella1,
- Andrea Garcia-Garijo1,
- Jara Palomero1,
- Anna Yuste-Estevanez1,
- Florian Erhard2,
- Juan Martín-Liberal3,
- Maria Ochoa de Olza3,
- Ignacio Matos3,
- Jared J. Gartner4,
- Michael Ghosh5,
- Francesc Canals6,
- August Vidal7,
- Josep Maria Piulats8,
- Xavier Matias-Guiu7,
- Irene Braña3,
- Eva Muñoz-Couselo9,
- Elena Garralda3,
- Andreas Schlosser2 and
- Alena Gros1,*
- 1Tumor Immunology and Immunotherapy, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital, Barcelona, Spain
- 2Rudolf Virchow Center, Center for Integrative and Translational Bioimaging, Julius-Maximilians-University Würzburg, Germany
- 3Early Drug Development Unit (UITM) Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital, Barcelona, Spain
- 4Surgery Branch, National Cancer Institute (NCI), National Institutes of Health, Bethesda, Maryland, USA
- 5Institute for Cell Biology Department of Immunology, University of Tübingen, Germany
- 6Proteomics, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital, Barcelona, Spain
- 7Department of Pathology. Hospital Universitari de Bellvitge-IDIBELL. CIBERONC
- 8Medical Oncology, Catalan Institute of Cancer (ICO), IDIBELL-Oncobell, Hospitalet de Llobregat, Spain
- 9Melanoma and other skin tumors unit, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital
- ↵*Corresponding Author:
Alena Gros, Email: agros{at}vhio.net, Address: c/ Natzaret 115-117, Cellex Center Lab 4.04A, 08035 Barcelona, Spain